License and collaboration revenue [USD, thousands]

Research and development [USD, thousands]

General and administrative [USD, thousands]

Total operating expenses [USD, thousands]

Loss from operations [USD, thousands]

Change in fair value of derivative liabilities [USD, thousands]

Change in fair value of non-controlling equity investments [USD, thousands]

Change in fair value of contingent consideration liabilities [USD, thousands]

Interest and other income (expense), net [USD, thousands]

Total other income (expense) [USD, thousands]

Net loss [USD, thousands]

Unrealized gain (loss) on marketable securities [USD, thousands]

Comprehensive loss [USD, thousands]

Net loss per common share, basic and diluted [USD]

Weighted-average common shares outstanding, basic and diluted [Shares]

7c54f77a9df2c54ad3a5b94d5de8e3a02f2e8d2af2b3f8493207124db69b09a3

Net Loss (USD, thousands)

Depreciation and Amortization (USD, thousands)

Amortization of Investment Discount (Premiums) (USD, thousands)

Stock-Based Compensation Expense (USD, thousands)

Change in Operating Lease Right-of-Use Assets (USD, thousands)

Change in Fair Value of Derivative Liabilities (USD, thousands)

Change in Fair Value of Contingent Consideration Liabilities (USD, thousands)

Change in Fair Value of Non-Controlling Equity Investments (USD, thousands)

Net Cash Provided by (Used in) Operating Activities (USD, thousands)

Purchases of Property and Equipment (USD, thousands)

Purchases of Marketable Securities (USD, thousands)

Maturities of Marketable Securities (USD, thousands)

Net Cash Provided by (Used in) Investing Activities (USD, thousands)

Proceeds from Issuance of Common Shares, Net of Commissions (USD, thousands)

Proceeds from Issuances of Stock Under ESPP (USD, thousands)

Equipment Financings, Net / Repayment of Equipment Financings (USD, thousands)

Proceeds from Exercise of Stock Options (USD, thousands)

Net Cash Provided by (Used in) Financing Activities (USD, thousands)

Net Change in Cash, Cash Equivalents and Restricted Cash (USD, thousands)

Cash Paid for Interest (USD, thousands)

Property and Equipment Additions in Accounts Payable and Accrued Expenses (USD, thousands)

Operating Lease Liabilities Arising from Obtaining Right-of-Use Assets (USD, thousands)

Prepaid Expenses and Other Current Assets (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Expenses and Other Liabilities (USD, thousands)

Operating Lease Liabilities (USD, thousands)

Deferred Revenue (USD, thousands)

Other Long-Term Liabilities (USD, thousands)

Cash, Cash Equivalents and Restricted Cash—Beginning of Period (USD, thousands)

Cash, Cash Equivalents and Restricted Cash—End of Period (USD, thousands)

0b261046b5c2ecfb99a90a374d896b5684e92697873ac3c2d69f2fd814a5e6d4

Size of manufacturing facility in North Carolina (square feet)

3509200417e86064838350207326ec10d81544228b25e9bcd396c06105843adc

License and Collaboration

- Apellis Agreement

- Other Agreements

Total Revenue

b4e0f99e1a5e69c37a72358dbb53a0cc0b742c5bcf0c270d822bdf683b51026d

Total assets (USD, thousands)

Total liabilities (USD, thousands)

Total stockholders’ equity (USD, thousands)

cd14c41801fecc8d0ef5099ccfe8076f80a16bbbcb764298c3f668103b41e66a

Beam Therapeutics Inc (BEAM)

Financials